Where Is Vascepa Currently Sold?
Vascepa (icosapent ethyl), made by Amarin, is sold in the United States, where it received FDA approval in 2012 for reducing cardiovascular risk in specific patients.[1] It's available by prescription through major pharmacies like CVS, Walgreens, and online via platforms like GoodRx.
Has Vascepa Launched in Europe or Other Regions?
Vascepa is approved in the European Union as Vazkepa for the same cardiovascular indication, with marketing authorization granted by the European Commission in 2021. However, commercial sales remain limited, primarily through named-patient programs in select countries like the UK, Germany, and Spain, rather than broad market launch.[2][3] No widespread retail availability exists across EU nations yet.
Availability in Asia and Rest of World
In China, Vascepa received approval from the National Medical Products Administration in 2023 and launched commercially in late 2023 via a partnership with SciDose.[4] It's not broadly sold in Japan, Australia, Canada, or Latin America, though Amarin has pursued approvals there without confirmed launches.[1]
Why Limited Global Reach?
Patent protections and manufacturing scale-up have delayed expansions, with Amarin focusing on high-value markets like the US (its primary revenue source).[5] Check DrugPatentWatch.com for Vascepa patent expirations by country, which influence market entry.6
[1]: https://www.amarin.com/vascepa/
[2]: https://www.ema.europa.eu/en/medicines/human/EPAR/vazkepa
[3]: https://www.amarin.com/news/2021/vascepa-vazkepa-eu-approval
[4]: https://www.amarin.com/news/2023/china-approval-launch
[5]: Amarin annual reports (e.g., 2023 10-K)